Understanding attitudes and behaviors towards cell-free DNA-based noninvasive prenatal testing (NIPT): A survey of European health-care providers
Benachi A., Caffrey J., Calda P., Carreras E., Jani J. C., Kilby M. D., Klein H. -., Ritstso D., Yaron Y.
European Journal of Medical Genetics
Vol.63, Issue1, Num.103616
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.1016/j.ejmg.2019.01.006
Аннотация:
Cell-free DNA-based noninvasive prenatal testing (cfDNA) is a relatively new screening tool that analyzes cfDNA circulating in maternal plasma to screen for aneuploidies. Since its introduction, cfDNA has been rapidly adopted by health care providers (HCPs). This rapid adoption, as well as progressive developments in the technology, requires professional societies to continuously update their guidelines to indicate the broadening scope both in terms of test indications and patient populations for whom it has become the appropriate primary test. CfDNA testing, initially applied to high-risk patients, is now largely considered an option for all patients. For HCPs, the rapid introduction of cfDNA into clinical practice has come with the requirement to stay up-to-date and accurately informed. We performed a survey to understand the current practices and views of European HCPs on the use of cfDNA. European HCPs were surveyed on several topics such as familiarity with cfDNA-based noninvasive
Ключевые слова:
Cell-free DNA; Europe; Health care provider; Noninvasive prenatal testing; Survey
cell free DNA; DNA; unclassified drug; cell free nucleic acid; aneuploidy; Article; clinical practice; European; female; France; genetic screening; genome-wide association study; gynecologist; health care personnel; high risk patient; human; live birth; male; maternal plasma; obstetrician; patient counseling; patient referral; population; prenatal care; prenatal diagnosis; prenatal screening; reimbursement; attitude; blood; Down syndrome; epidemiology; ethics; Europe; genetics; Germany; health care personnel; Italy; pregnancy; psychology; questionnaire; Spain; Aneuploidy; Attitude; Cell-Free Nucleic Acids; Down Syndrome; Europe; Female; France; Germany; Health Personnel; Humans; Italy; Noninvasive Prenatal Testing; Pregnancy; Spain; Surveys and Questionnaires
Язык текста: Английский
ISSN: 1878-0849
Benachi A.
Caffrey J.
Calda P.
Carreras E.
Jani J. C.
Kilby M. D.
Klein H. -. H.-G.
Ritstso D. Dzhuzeppe 1958-
Yaron Y.
Беначи А.
Cаффреy Й.
Cалда П.
Cаррерас Е.
Йани Й. C.
Килбy М. Д.
Клеин Х. -. Х.-Г.
Риццо Д. Джузеппе 1958-
Ярон Y.
Understanding attitudes and behaviors towards cell-free DNA-based noninvasive prenatal testing (NIPT): A survey of European health-care providers
Текст визуальный непосредственный
European Journal of Medical Genetics
Elsevier Science Publisher B.V.
Vol.63, Issue1 Num.103616
2020
Статья
Cell-free DNA Europe Health care provider Noninvasive prenatal testing Survey
cell free DNA DNA unclassified drug cell free nucleic acid aneuploidy Article clinical practice European female France genetic screening genome-wide association study gynecologist health care personnel high risk patient human live birth male maternal plasma obstetrician patient counseling patient referral population prenatal care prenatal diagnosis prenatal screening reimbursement attitude blood Down syndrome epidemiology ethics Europe genetics Germany health care personnel Italy pregnancy psychology questionnaire Spain Aneuploidy Attitude Cell-Free Nucleic Acids Down Syndrome Europe Female France Germany Health Personnel Humans Italy Noninvasive Prenatal Testing Pregnancy Spain Surveys and Questionnaires
Cell-free DNA-based noninvasive prenatal testing (cfDNA) is a relatively new screening tool that analyzes cfDNA circulating in maternal plasma to screen for aneuploidies. Since its introduction, cfDNA has been rapidly adopted by health care providers (HCPs). This rapid adoption, as well as progressive developments in the technology, requires professional societies to continuously update their guidelines to indicate the broadening scope both in terms of test indications and patient populations for whom it has become the appropriate primary test. CfDNA testing, initially applied to high-risk patients, is now largely considered an option for all patients. For HCPs, the rapid introduction of cfDNA into clinical practice has come with the requirement to stay up-to-date and accurately informed. We performed a survey to understand the current practices and views of European HCPs on the use of cfDNA. European HCPs were surveyed on several topics such as familiarity with cfDNA-based noninvasive